NEW YORK, Jan. 26, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX) today announced the commercial launch of BRIUMVI™ (ublituximab-xiiy), for the treatment of relapsing forms of multiple ...
Half a year after the FDA snatched back an approval for TG Therapeutics’ first-in-class lymphoma med Ukoniq, the company has landed a regulatory win. Wednesday, TG snared U.S. approval for its ...
TG Therapeutics recently completed a US$100 million share repurchase program, buying back approximately 3.5 million shares, and the Board of Directors has authorized an additional US$100 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results